Form D · Pharmaceuticals
VBI Vaccines Inc/BC
Cambridge, MA · CIK 0000764195
Offering snapshot reported Sep 28, 2022 · SEC filing
- Reported sold
- $0 Offering amount: $0
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 28, 2022 | Initial | $0 | No comparison | 1 | SEC filing |
| May 27, 2020 | Initial | $4,700,000 | No comparison | 1 | SEC filing |
| May 1, 2020 | Initial | $1,057,500 | No comparison | 61 | SEC filing |
| Dec 7, 2018 | Initial | $7,000,000 | No comparison | 1 | SEC filing |
| Dec 20, 2016 | Initial | $10,598,750 | No comparison | 2 | SEC filing |
| Jul 5, 2016 | Initial | $13,609,749 | No comparison | 3 | SEC filing |
| Nov 6, 2014 | Initial | $4,400,000 | No comparison | 11 | SEC filing |
| Sep 10, 2010 | Initial | $274,685 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-460161
Company's lenders may convert $7mil of certain loans to the Company into 6,161,889 shares and may exercise a warrant for 2,180,413 shares. Lenders may make additional loans, entitling them to exercise the warrant for up to an additional 2,180,413 shares.
Source: Form D, filed Sep 28, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David E. Anderson | Executive |
| Ron Barbaro | Director |
| Jeffrey R. Baxter | Director, Executive |
| Jeff Baxter | Director, Executive |
| Nell Beattie | Executive |
| Damian Braga | Director |
| Annie Chan | Executive |
| Sam Chawla | Director |
| Victor Chevillon | Director, Executive |
| Vic Chevillon | Director, Executive |
| Dorothy Chin | Executive |
| Joanne Cordeiro | Director |
| Michel De Wilde | Director |
| Francisco Diaz Mitoma | Executive |
| Carlos H. Fernandez Mazzi | Director |
| Steven Gillis | Director |
| Steve Gillis | Director |
| William C. Glasier | Director |
| Tomer Kariv | Director |
| Athena Kartsaklis | Executive |
| Curt Lockshin | Executive |
| Adam Logal | Director |
| James Martin | Executive |
| Avi Mazaltov | Executive |
| Blaine Mc Kee | Director |
| Christopher Mc Nulty | Executive |
| Egidio Nascimento | Executive |
| Scott Requadt | Director |
| Robert Roberts | Director |
| Gary Robertson | Director |
| Steven Rubin | Director |
| Lisa Sharp | Executive |
| Ron Tremblay | Director, Executive |
| Louis Wolfin | Director, Executive |
| David Wolfin | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
160 Second Street Floor 3
Cambridge, MA, 02142
Cambridge, MA, 02142